The stock of XOMA Corp (NASDAQ:XOMA) reached all time low today, Oct, 19 and still has $4.47 target or 14.00% below today’s $5.20 share price. This indicates more downside for the $31.35M company. This technical setup was reported by Barchart.com. If the $4.47 PT is reached, the company will be worth $4.39M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 146,833 shares traded hands or 146.10% up from the average. XOMA Corp (NASDAQ:XOMA) has declined 60.00% since March 16, 2016 and is downtrending. It has underperformed by 65.54% the S&P500.
Analysts await XOMA Corp (NASDAQ:XOMA) to report earnings on November, 3. They expect $-0.12 earnings per share, up 33.33% or $0.06 from last year’s $-0.18 per share. After $-0.13 actual earnings per share reported by XOMA Corp for the previous quarter, Wall Street now forecasts -7.69% EPS growth.
XOMA Corp (NASDAQ:XOMA) Ratings Coverage
Out of 5 analysts covering Xoma Limited (NASDAQ:XOMA), 1 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 20% are positive. Xoma Limited has been the topic of 8 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Wednesday, July 22 by Piper Jaffray. The company was downgraded on Wednesday, July 22 by Ladenburg Thalmann. The rating was downgraded by Zacks on Friday, August 28 to “Buy”. Zacks downgraded XOMA Corp (NASDAQ:XOMA) on Friday, September 4 to “Hold” rating. The firm earned “Buy” rating on Wednesday, August 5 by Wedbush. The firm has “Hold” rating by Jefferies given on Thursday, July 23.
According to Zacks Investment Research, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ÃŸ with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California.”
Insitutional Activity: The institutional sentiment decreased to 0.59 in 2016 Q2. Its down 0.72, from 1.31 in 2016Q1. The ratio fall, as 22 funds sold all XOMA Corp shares owned while 22 reduced positions. 16 funds bought stakes while 10 increased positions. They now own 20.41 million shares or 36.27% less from 32.03 million shares in 2016Q1.
Whittier Trust, a California-based fund reported 33 shares. Moreover, Commonwealth Equity Service Inc has 0% invested in XOMA Corp (NASDAQ:XOMA) for 11,082 shares. Citigroup Incorporated has invested 0% of its portfolio in XOMA Corp (NASDAQ:XOMA). Renaissance Technology Llc has 0% invested in the company for 461,220 shares. The Connecticut-based Paloma Partners Mngmt Company has invested 0% in XOMA Corp (NASDAQ:XOMA). Blackrock Institutional Tru Com Na reported 1.93M shares or 0% of all its holdings. Gotham Asset Limited Liability last reported 13,497 shares in the company. Blackrock Advisors Limited accumulated 0% or 46,795 shares. Deutsche Financial Bank Ag has 182,178 shares for 0% of their US portfolio. Millennium Ltd last reported 721,288 shares in the company. California Employees Retirement Sys last reported 0% of its portfolio in the stock. Lucas Mgmt holds 0% of its portfolio in XOMA Corp (NASDAQ:XOMA) for 10,000 shares. Huntington Comml Bank accumulated 624 shares or 0% of the stock. Academy Capital Inc Tx owns 12,755 shares or 0% of their US portfolio. Creative Planning has 0% invested in the company for 15,405 shares.
XOMA Company Profile
XOMA Corporation, incorporated on December 31, 2011, is a development-stage biotechnology firm with a portfolio of therapeutic antibodies. The Firm focuses on the discovery and development of monoclonal antibody therapeutics. The Firm has over five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. The Company’s products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. The Company’s XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. The Company’s endocrine portfolio also includes a Phase II-ready product candidate, XOMA 213, targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.